Truist Securities Raises Jazz Pharmaceuticals (JAZZ) Price Target After HERIZON-GEA Trial

Group 1 - Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is recognized as a mid-cap stock to buy, with Truist Securities raising its price target to $230 from $220 while maintaining a Buy rating [1] - The increase in price target is attributed to positive results from the HERIZON-GEA trial, leading to higher estimations for Ziihera [1][3] - Jazz Pharmaceuticals plans to file a supplemental Biologics License Application (sBLA) in the first half of 2026 to obtain a broad label for first-line gastroesophageal adenocarcinoma (GEA) as both doublet and triplet therapy [2] Group 2 - Truist Securities expects strong commercial adoption of Jazz Pharmaceuticals' products following clearance based on clinical data, with over 90% prescriber crossover between GEA and biliary tract cancer (BTC) [3] - The company develops treatments for serious illnesses, with key products including Xywav, Xyrem, Epidiolex, Rylaze, Zepzelca, Defitelio, and Vyxeos [3]